Wegovy (semaglutide) will no longer be available through Hims & Hers Health, as Novo Nordisk has ended its short-lived partnership.

Hims & Hers Health delivered a first quarter that surpassed Wall Street’s expectations, driven by strong adoption of its ...

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Hims & Hers Health, ...

There is always a challenging moment in every investor’s favorite stock and portfolio, especially when said businesses are ...

IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN HIMS & HERS HEALTH, INC. (HIMS), CONTACT THE LAW OFFICES OF HOWARD G. SMITH BEFORE AUGUST 25, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING ...